It’s been a difficult week for atai Life Sciences, with the company’s stock price tacking a tumble as pre-IPO shares became eligible for trading. Despite efforts by insiders, including voluntary extended lock-ups announced by the company on Wednesday itself, ATAI was down nearly 40% on the lock-up expiry day. COMPASS Pathways looks set to enter a spot of bother, too. VICE’s Shayla Love broke the…
